United States was Incyte’s largest region in fiscal 2025, bringing in $4.89B of $5.23B (93%).
| Geography | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| United States | $3.31B | $3.51B | $4.11B | $4.89B | ||||
| U.S | — | — | — | — | ||||
| Europe | $147.00M | $175.87M | — | $323.73M | ||||
| Non-U.S | — | — | — | — | ||||
| Other Countries | — | $4.91M | $6.21M | $17.57M | ||||
| Total | $3.46B | $3.70B | $4.11B | $5.23B |
Incyte brought in $5.23B from its three regions in fiscal 2025, the year ended December 31, 2025. Incyte regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $4.11B. United States was the largest at $4.89B (93.5%), ahead of Europe at $323.73M (6.2%) and Other Countries at $17.57M (0.3%).
Incyte began breaking out Other Countries in fiscal 2023, when it brought in $4.91M.
Jakafi was Incyte’s largest product and service line in fiscal 2021, bringing in $2.23B of $2.98B (75%).
| Product and Service | FY 2013 | FY 2014 | FY 2014 | FY 2014 | FY 2015 | FY 2015 | FY 2015 | FY 2016 | FY 2016 | FY 2016 | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2020 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jakafi | — | — | — | $63.00M | — | — | — | $1.68B | — | — | — | $1.94B | $2.23B | |||||||||||||||
| Product Revenues, Net | $334.50M | $365.50M | $367.70M | — | $396.20M | $433.90M | $454.00M | — | $486.70M | $500.30M | $522.30M | — | — | |||||||||||||||
| Jakavi | — | — | — | $900.00M | — | — | — | — | — | — | — | $277.90M | — | |||||||||||||||
| Jakafi & Iclusig | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||
| Jakavi Royalty Revenues | — | — | — | $194.69M | — | — | — | $225.91M | — | — | — | — | — | |||||||||||||||
| Olumiant | — | — | — | — | — | — | — | — | — | — | — | $110.90M | $220.90M | |||||||||||||||
| Milestone & Contract Revenues | — | $100.00M | $20.00M | $180.00M | $40.00M | $20.00M | $17.50M | $77.50M | — | $95.00M | — | — | $95.00M | |||||||||||||||
| Olumiant Royalty Revenues | — | — | — | $40.09M | — | — | — | $80.42M | — | — | — | $110.92M | $220.88M | |||||||||||||||
| Iclusig | — | — | — | $79.94M | — | — | — | — | — | — | — | $105.00M | $109.40M | |||||||||||||||
| Product Royalty Revenues | $47.70M | $56.00M | $61.90M | $234.78M | $61.60M | $76.00M | $80.10M | — | $81.80M | $92.80M | $98.40M | — | — | |||||||||||||||
| Pemazyre | — | — | — | — | — | — | — | $89.95M | — | — | — | $25.88M | $68.53M | |||||||||||||||
| Tabrecta Royalty Revenues | — | — | — | — | — | — | — | — | — | — | — | $4.14M | $10.39M | |||||||||||||||
| Tabrecta | — | — | — | — | — | — | — | — | — | — | — | $4.10M | $10.40M | |||||||||||||||
| Minjuvi | — | — | — | — | — | — | — | — | — | — | — | — | $4.91M | |||||||||||||||
| Opzelura | — | — | — | — | — | — | — | — | — | — | — | — | $4.67M | |||||||||||||||
| Other Revenues | — | — | — | $203.00K | — | — | — | — | — | — | — | — | — | |||||||||||||||
| Total | $382.20M | $521.50M | $449.60M | $1.69B | $497.80M | $529.90M | $551.60M | $2.16B | $568.50M | $688.10M | $620.70M | $2.58B | $2.98B |
Incyte brought in $2.98B from its 10 product and service lines in fiscal 2021, the year ended December 31, 2021. Incyte regrouped these lines after fiscal 2020, so the total does not compare directly with that year's $2.58B. Jakafi was the largest at $2.23B (75.0%), ahead of Olumiant at $220.90M (7.4%) and Olumiant Royalty Revenues at $220.88M (7.4%). The other seven lines brought in $303.29M combined.
Compared with fiscal 2020, Pemazyre grew fastest, up 164.8% to $68.53M. Every line above 2% of revenue grew.
Incyte began breaking out Olumiant in fiscal 2020, Pemazyre in fiscal 2019, Tabrecta Royalty Revenues in fiscal 2020 and Tabrecta in fiscal 2020. Incyte stopped reporting Product Revenues, Net ($522.30M in fiscal 2020), Jakavi ($277.90M in fiscal 2020), Jakavi Royalty Revenues ($225.91M in fiscal 2019) and two others as separate lines.
Incyte (INCY) reports its revenue by geography and by product and service. In fiscal 2025, United States was its largest region, bringing in $4.89B (93.5% of the total), followed by Europe at $323.73M (6.2%).
United States was Incyte's largest region in fiscal 2025, bringing in $4.89B, or 93.5% of the $5.23B total across its three regions.
Jakafi was Incyte's largest product and service line in fiscal 2021, bringing in $2.23B, or 75.0% of the $2.98B total across its 10 product and service lines.
Every figure comes from Incyte's annual financial filings, as reported. Each line keeps the name Incyte gives it, and years follow its fiscal calendar.
Incyte's revenue by geography goes back to fiscal 2018, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.